The evidence from clinical trials on colchicine and corticosteroids’ effect on COVID-19: a systematic review and meta-analysis

References

• Tzotzos SJ, Fischer B, Fischer H, et al. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care. 2020;24(1):516.
   PubMed Web of Science ®Google Scholar
• Khanmohammadi S, Rezaei N. Role of toll-like receptors in the pathogenesis of COVID-19. J Med Virol. 2021;93(5):2735–2739.
   PubMed Web of Science ®Google Scholar
• Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-19. Nat Med. 2021;27(10):1674–1675.
   PubMed Web of Science ®Google Scholar
• Bitar AN, Ghoto MA, Dayo A, et al. Pathophysiological correlation between diabetes mellitus Type-II and chronic obstructive pulmonary diseases. J Liaquat Univ Med Health Sci. 2017;16:41–48.
   Web of Science ®Google Scholar
• Dalbeth N, Lauterio TJ, Wolfe HR. Mechanism of action of colchicine in the treatment of gout. Clin Ther. 2014;36(10):1465–1479.
   PubMed Web of Science ®Google Scholar
• Mareev VY, Orlova YA, Plisyk AG, et al. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study. Kardiologiia. 2021;61(2):15–27.
   PubMed Web of Science ®Google Scholar
• Scarsi M, Piantoni S, Colombo E, et al. Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome. Ann Rheum Dis. 2020;79(10):1286–1289.
   PubMed Web of Science ®Google Scholar
• Absalón-Aguilar A, Rull-Gabayet M, Pérez-Fragoso A, et al. Colchicine is safe though ineffective in the treatment of severe COVID-19: a randomized clinical trial (COLCHIVID). J Gen Intern Med. 2022;37(1):4–14.
   PubMed Web of Science ®Google Scholar
• Bitar AN, Sulaiman SAS, Ali IABH, et al. Prevalence, risk assessment, and predictors of osteoporosis among chronic obstructive pulmonary disease patients. J Adv Pharm Technol Res. 2021;12(4):395–401.
   PubMed Web of Science ®Google Scholar
• Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr. 2021;133(7–8):303–311.
   PubMed Web of Science ®Google Scholar
• Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Correction to: methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1):436.
   PubMed Web of Science ®Google Scholar
• Bitar AN, Zawiah M, Al-Ashwal F, et al. Misinformation, perceptions towards COVID-19 and willingness to be vaccinated: a population-based survey in Yemen. PLoS ONE 2021;16(10):e0248325.
   Google Scholar
• Cochrane Handbook for Systematic Reviews of Interventions. https://training.cochrane.org/handbook/current.
   Google Scholar
• Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open. 2020;3(6):e2013136.
   PubMed Web of Science ®Google Scholar
• Diaz R, Orlandini A, Castellana N, et al. Effect of colchicine vs usual care alone on intubation and 28-day mortality in patients hospitalized with COVID-19: a randomized clinical trial. JAMA Netw Open. 2021;4(12):e2141328.
   PubMed Web of Science ®Google Scholar
• Pascual-Figal DA, Roura-Piloto AE, Moral-Escudero E, et al. Colchicine in recently hospitalized patients with COVID-19: a randomized controlled trial (COL-COVID). Int J Gen Med. 2021;14:5517–5526.
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Bouabdallaoui N, L'Allier PL, et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. Lancet Respir. Med. 2021;9(8):924–932.
   PubMed Web of Science ®Google Scholar
• RECOVERY Collaborative Group Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet Respir. Med. 2021;9:1419–1426.
   PubMed Web of Science ®Google Scholar
• Lopes MI, Bonjorno LP, Giannini MC, et al. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7(1):e001455.
   PubMed Web of Science ®Google Scholar
• Jeronimo CMP, Farias MEL, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2021;72(9):e373–e381.
   PubMed Web of Science ®Google Scholar
• Edalatifard M, Akhtari M, Salehi M, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56(6):2002808.
   PubMed Web of Science ®Google Scholar
• Solanich X, Antolí A, Rocamora-Blanch G, et al. Methylprednisolone pulses plus tacrolimus in addition to standard of care vs. standard of care alone in patients with severe COVID-19. A randomized controlled trial. Front Med. 2021;8:691712.
   Web of Science ®Google Scholar
• Hamed DM, Belhoul KM, Al Maazmi NA, et al. Intravenous methylprednisolone with or without tocilizumab in patients with severe COVID-19 pneumonia requiring oxygen support: a prospective comparison. J Infect Public Health. 2021;14(8):985–989.
   PubMed Web of Science ®Google Scholar
• Pinzón MA, Ortiz S, Holguín H, et al. Dexamethasone vs methylprednisolone high dose for covid-19 pneumonia. PLOS One. 2021;16(5):e0252057.
   PubMed Web of Science ®Google Scholar
• Tang X, Feng Y-M, Ni J-X, et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind, randomized control trial. Respir. Int. Rev. Thorac. Dis. 2021;100(2):116–126.
   Google Scholar
• Sancho-López A, Caballero-Bermejo AF, Ruiz-Antorán B, et al. Efficacy and safety of sarilumab in patients with COVID19 pneumonia: a randomized, phase III clinical trial (SARTRE study). Infect Dis Ther. 2021;10(4):2735–2748.
   PubMed Web of Science ®Google Scholar
• Ghanei M, Solaymani-Dodaran M, Qazvini A, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respir Res. 2021;22(1):245.
   PubMed Web of Science ®Google Scholar
• Chiu L, Lo C-H, Shen M, et al. Colchicine use in patients with COVID-19: a systematic review and meta-analysis. PLOS One. 2021;16(12):e0261358.
   PubMed Web of Science ®Google Scholar
• Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.
   PubMed Web of Science ®Google Scholar
• Bitar AN, Sulaiman SAS, Ali IAH, et al. Osteoporosis among patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of prevalence, severity, and therapeutic outcomes. J Pharm Bioallied Sci. 2019;11(4):310–320.
   PubMed Web of Science ®Google Scholar
• Cumhur Cure M, Kucuk A, Cure E. Colchicine may not be effective in COVID-19 infection; it may even be harmful? Clin Rheumatol. 2020;39(7):2101–2102.
   PubMed Web of Science ®Google Scholar
• Stewart S, Yang KCK, Atkins K, et al. Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28.
   PubMed Web of Science ®Google Scholar
• Mehta KG, Patel T, Chavda PD, et al. Efficacy and safety of colchicine in COVID-19: a meta-analysis of randomised controlled trials. RMD Open. 2021;7(3):e001746.
   PubMed Web of Science ®Google Scholar
• Bitar SM, Moussa M. The risk factors for the recurrent upper gastrointestinal hemorrhage among acute peptic ulcer disease patients in Syria: a prospective cohort study. Ann Med Surg. 2022;74:103252.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Torres A. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm? Eur Respir Rev. 2021;30:200346.
   PubMed Web of Science ®Google Scholar
• Tlayjeh H, Mhish OH, Enani MA, et al. Association of corticosteroids use and outcomes in COVID-19 patients: a systematic review and meta-analysis. J Infect Public Health. 2020;13(11):1652–1663.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Murthy S, Diaz JV, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–1341.
   PubMed Web of Science ®Google Scholar
• Ebrahimi Chaharom F, Pourafkari L, Ebrahimi Chaharom AA, et al. Effects of corticosteroids on covid-19 patients: a systematic review and meta-analysis on clinical outcomes. Pulm Pharmacol Ther. 2022;72:102107.
   PubMed Web of Science ®Google Scholar
• Polak SB, Van Gool IC, Cohen D, et al. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020;33(11):2128–2138.
   PubMed Web of Science ®Google Scholar
• Ahmed Z, Aziz S, Alauddin S, et al. In vitro cytotoxic and antimicrobial activities of erythrina suberosa (roxb) bark. J Pharm Bioallied Sci. 2020;12(2):210–216.
   PubMed Web of Science ®Google Scholar
• Villar J, Ferrando C, Martínez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–276.
   PubMed Web of Science ®Google Scholar
• Little P. Non-steroidal anti-inflammatory drugs and covid-19. BMJ. 2020;368:m1185.
   PubMed Web of Science ®Google Scholar
• Robb CT, Goepp M, Rossi AG, et al. Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19. Br J Pharmacol. 2020;177(21):4899–4920.
   PubMed Web of Science ®Google Scholar
• Lammi C, Arnoldi A. Food-derived antioxidants and COVID-19. J Food Biochem. 2021;45(1):e13557.
   PubMed Web of Science ®Google Scholar
• Pardo E, Constantin J-M, Bonnet F, et al. Nutritional support for critically ill patients with COVID-19: new strategy for a new disease? Anaesth Crit Care Pain Med. 2020;39(6):738–739.
   PubMed Web of Science ®Google Scholar